New long-term extension data show approximately 80% of patients achieved or maintained meaningful skin improvement (EASI 75) with EBGLYSS with half the doses compared to approved monthly maintenance ...
--New results show Eli Lilly and Company's EBGLYSS achieved deep and sustained response for patients with moderate-to-severe atopic dermatitis at three years. These findings from the ADjoin long-term ...
EBGLYSS is an interleukin-13 (IL-13) inhibitor that selectively blocks IL-13 signaling with high binding affinity. 2,3,4 The cytokine IL-13 is a primary cytokine in atopic dermatitis, driving the type ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results